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An imipenem-resistant Enterobacter cloacae isolate
was recovered from the blood of a patient with a hemato-
logic malignancy. Analytical isoelectric focusing, inhibitor
studies, hydrolysis, induction assays, and molecular
sequencing methods confirmed the presence of a NmcA
carbapenem-hydrolyzing enzyme. This first report of NmcA
detected in North America warrants further investigation
into its distribution and clinical impact.
C
arbapenem resistance mediated by acquired carbapen-
emases is a growing concern worldwide (1–3).
Carbapenems are the most potent of β-lactam antibiotics
with a broad spectrum of activity against aerobic and
anaerobic bacterial pathogens. These antibiotics are also
the most reliable of the β-lactams for treatment of infec-
tions caused by organisms that produce extended-spectrum
β-lactamases (ESBLs) or AmpC β-lactamases (4,5).
Intrinsic resistance does occur, however, in a number of
species, including Bacillus cereus, Stenotrophomonas mal-
tophilia,  Flavobacterium  sp. and Chryseobacterium sp.,
Aeromonas hydrophila,  Legionella gormanii, and
Janthinobacterium lividum, because of the presence of
metallo-β-lactamases (1). Acquired carbapenemases, on
the other hand, are a heterogeneous mixture of enzymes
that belong to Ambler class A, B, or D enzymes and may
be plasmid or chromosomally encoded (1,2). Here we
describe the characterization of imipenem resistance
attributable to an acquired class A carbapenem-hydrolyz-
ing enzyme, NmcA, in an Enterobacter cloacae isolate.
The Study
A 33-year-old man with acute myeloid leukemia was
admitted to a hospital in Seattle, Washington, with neu-
tropenic fever; he was initially treated with ceftazidime.
His therapy was changed to acyclovir and imipenem
because of unremitting fevers and oral lesions positive for
herpes simplex virus type 1, whereupon his fever defer-
vesced immediately. The fever recurred 2 weeks after
treatment was begun, and imipenem-resistant E. cloacae
was isolated from the blood. After the results of suscepti-
bility testing were obtained, his therapy was changed to
levofloxacin, and he exhibited a good clinical response. 
The E. cloacae isolate was susceptible to piperacillin,
piperacillin-tazobactam, ceftazidime, ceftriaxone,
cefepime, ciprofloxacin, gentamicin, aztreonam, and
trimethoprim-sulfamethoxazole and was resistant to ampi-
cillin, amoxicillin-clavulanic acid, cefazolin, and cefox-
itin. By both disk diffusion and E-test methods (AB
Biodisk, Solna, Sweden), the zones of inhibition around
the imipenem, meropenem, and ertapenem disks were
indistinct, with inner colonies extending up to the disk or
the highest concentration on the E-test strip (MIC >32
µg/mL) and were interpreted as resistant (Figure 1).
Addition of 10 µL of 1,000 µg/mL clavulanic acid to the
imipenem, meropenem, and ertapenem disks resulted in
clearly defined and enlarged zones of inhibition and loss of
the inner colonies (Figure 2). Using either cefoxitin or
imipenem as inducers by the disk induction method result-
ed in the formation of blunted or D-shaped zones of inhi-
bition to meropenem and ertapenem (6). We performed a
carbapenem bioassay by incubating 100 µL of a 50 µg/mL
solution of each carbapenem (imipenem, meropenem, or
ertapenem) with 100 µL of either crude β-lactamase
extract or phosphate-buffered saline for 90 min at room
temperature. The inactivating capacity of the enzyme was
then tested by a disk diffusion assay that demonstrated
hydrolysis of imipenem, meropenem, and ertapenem (7).
Isoelectric focusing (IEF) to determine isoelectric
points (pIs) and general inhibitor characteristics with an
ampholine polyacrylamide gel (pH range 3.5–9.5) on a
flatbed apparatus (Multiphor LKB, Bromma, Stockholm,
Sweden) indicated that this organism produced a β-lacta-
mase enzyme with a pI of 6.9 that was inhibited by clavu-
lanic acid and not by cloxacillin (8,9). This enzyme
hydrolyzed 1 µg/mL imipenem on the IEF gel overlay.
Inducibility of the enzyme by imipenem (4 mg/L) and
cefoxitin (8 mg/L) was confirmed by the broth induction
method and IEF (10). After the broth induction procedure,
the uninduced and induced preparations were serially
diluted in 0.1 M potassium phosphate buffer, pH 7.0, per-
mitting both qualitative and semiquantitative assessment
of enzyme activity among the various β-lactamases in the
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Glasgow, Scotland, 2003.isolate, as determined by IEF. The broth induction enzyme
preparation from a 100-mL, 3.5-h Mueller-Hinton broth
produced a visible but light AmpC band, pI >9.0. The
induction with cefoxitin and imipenem increased the levels
of both the AmpC and the pI 6.9 carbapenem-hydrolyzing
enzyme, as visualized in Figure 3. A cefoxitin-induced
preparation of E. cloacae NOR-1 (that produces NmcA)
was included as a control strain for IEF (11). 
Chromosomal DNA was extracted from overnight cul-
tures with the Qiagen DNeasy Tissue kit (QIAGEN Inc.,
Valencia, CA). Polymerase chain reaction (PCR)-amplifi-
cation with a thermal cycler (MJ Research PTC - 200-
DNA Engine, San Francisco, CA) was used to obtain a
2,122 base pair gene fragment consisting of the carbapen-
emase structural gene nmcA and its regulatory gene nmcR
(12,13). The nucleotide sequences of the primers were 5'-
TGC CAG CTT AAT TAT TTT CAG ATT AG -3' (nmcR
positions 32–56) and 5'- ATT TTT TTC ATG ATG AAG
TTA AGC C -3' (nmcA positions 2,129–2,154). PCR
amplification of the nmcR/nmcA genes showed positive
results with both NOR-1 and the strain under study, sug-
gesting that the latter strain harbored a carbapenem-
hydrolyzing enzyme similar to that of NOR-1 (11).
Subsequent sequence analysis of the amplified DNA-
region showed a similarity of 100% (2,122 base pairs)
between the sequence of our strain and the carbapenemase
genes, regulatory (nmcR) and structural (nmcA) genes of
the E. cloacae strain NOR-1 (13).
Conclusions 
Ambler class A carbapenem-hydrolyzing enzymes are
relatively rare and have been reported to date in only a
handful of isolates of Enterobacteriaceae worldwide
(1,2,14–16). Sme-1 was identified from two Serratia
marcescens strains collected in London in 1982, and IMI-
1 was found in two strains of E. cloacae isolated in south-
ern California in 1984. Both enzymes were retrospectively
characterized from clinical isolates recovered before car-
bapenems were marketed (17,18). Subsequently, imipen-
em-resistant  S. marcescens strains were identified from
Minnesota, California, and Boston during a 15-year peri-
od, 1985–1999. The Minnesota isolate produced an
enzyme identical to the London Sme-1 enzyme, but the
Boston and California strains produced a related Sme-1
enzyme with a single amino-acid variation, named Sme-2.
More recently, a fourth class A β-lactamase, KPC-1, has
been described in a strain of Klebsiella pneumoniae col-
lected in North Carolina (15).
NmcAwas the first class Acarbapenemase identified in
a clinical isolate of E. cloacae, NOR-1, in 1990, following
the introduction of carbapenems (11). This strain was
recovered from the pus of a fistulized subcutaneous
abscess of a hospitalized French patient who had received
one intravenous bolus (500 mg) of imipenem before the
strain isolation. The present strain was also isolated from
the patient during therapy with imipenem. Similar to the
NOR-1 isolate, this strain displayed decreased susceptibil-
ity to carbapenems (imipenem and meropenem) while
remaining fully susceptible to extended-spectrum
cephalosporins (1). The strain also had decreased suscepti-
bility to ertapenem. Although the zones of inhibition
around the carbapenem disks were poorly defined, leading
us to question the purity of the isolate, repeated testing
confirmed our initial observations. The carbapenem-
hydrolyzing enzyme was inhibited by clavulanic acid, as
shown by the disk diffusion method and confirmed by the
IEF overlay method, similar to the other class A carbapen-
em-hydrolyzing enzymes (1,2). We found that adding of
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Figure 1. Susceptibility testing of Enterobacter cloacae to carbapen-
ems. Both methods had ill-defined zones of inhibition with inner
colonies growing up to the disks or the E-test strips, respectively. 
Figure 2. Effect of addition of clavulanic acid (10 µL of 1,000
mg/mL) to the zones of inhibition of the three carbapenem disks.
Top row (left to right): imipenem, meropenem, and ertapenem
disks without clavulanic acid. Bottom row (left to right): imipenem,
meropenem, and ertapenem disks with clavulanic acid.clavulanic acid to the carbapenem disks, similar to the
method used for National Committee for Clinical
Laboratory Standards ESBL confirmatory testing, was a
simple and helpful diagnostic approach. Because other
investigators have defined the hydrolytic spectrum of the
NmcA enzyme, we have not established whether the
NmcA enzyme was solely responsible for the carbapenem
resistance in our isolate (11,13).
Class Acarbapenem-hydrolyzing β-lactamases are usu-
ally coproduced with other β-lactamases, conferring dis-
tinct biochemical advantages to the parent strain (3). The
carbapenem-hydrolyzing enzyme IMI-1 was produced
along with AmpC and TEM-type enzymes; Sme-1 was co-
produced along with a chromosomal AmpC (3,18). Our
strain was similar to NOR-1 and produced an AmpC
enzyme of pI >9.0 along with the carbapenem-hydrolyzing
enzyme of pI 6.9. The inducibility of NmcA in this strain
of E. cloacae by cefoxitin and imipenem was evident by
disk induction and confirmed by broth induction with IEF,
similar to the NOR-1 strain. Expression of NmcAhas been
shown to be inducible because of the presence of a LysR-
type regulatory gene, Nmc-R, which precedes the blaNMC-A
gene (1). NmcR mediates biosynthesis of the carbapene-
mase enzyme at the basal state, which is further increased
when β-lactam-mediated induction occurs (13). Naas et al.
have shown that NmcR acts as a positive regulator for car-
bapenemase biosynthesis even in the absence of an induc-
er (unlike Amp-R, which is a negative regulator of the
cephalosporinase expression in the AmpC-AmpR system)
and deletion of NmcR results in a sharp decrease in car-
bapenem MIC and loss of β-lactamase inducibility (13). A
recent study has shown that AmpD from E. cloacae NOR-
1 is involved in the regulation of expression of both β-lac-
tamases (NmcA and AmpC) (19). These findings suggest
that different structural genes may be under the control of
identical regulatory systems and that nucleotide substitu-
tions in AmpD could lead to the stable co-expression of the
NmcA together with overexpression of the AmpC enzyme
in E. cloacae (19).
This is the first report of the isolation of the NmcAcar-
bapenem-hydrolyzing enzyme from a clinical isolate of E.
cloacae in North America. The importance of this finding
for clinicians and laboratorians is illustrated by the follow-
ing: the NmcA enzyme is able to hydrolyze carbapenems;
the NmcA enzyme occurred in E. cloacae (a common
nosocomial pathogen); the NmcA enzyme was difficult to
detect; the NmcA enzyme is inducible; and the expression
of NmcA is coregulated with AmpC. Accurately identify-
ing the different mechanisms of carbapenem resistance
will help determine the epidemiology, risk factors, and
therapeutic options in each case. The continued emergence
of novel resistance mechanisms to carbapenems world-
wide reemphasizes the need not only for prudent carbapen-
em use but also for prudent antibiotic use in general.
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